All News
Should You Add MTX to a TNF Inhibitor in Psoriasis?
Target emulation trial shows adding methotrexate (MTX) to adalimumab (ADA) does not augment the effectiveness and persistence of adalimumab alone in treating plaque psoriasis in adults.
Read Article
Belimumab in SLE with Mucocutaneous or Vasculitis Findings
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.
Read Article
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
Read Article
Biologics in Pregnancy Patients With Autoimmune Disease
A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic arthri
Read Article
Panacea of Prednisone & Cannabis (5.16.2025)
Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com. Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!
Read Article
Target trial emulation study data from British Dermatologists Biologics & Immunomodulators Register, compared 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). https://t.co/DSYNd9P5Om
Dr. John Cush RheumNow ( View Tweet)
Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.89 million in 2021 ( range of 29.95-31.82 million) - highest in USA 550/100,000. High in N.America, S.America, Southeast Asia, Australia. Lowestin Africa, Middle https://t.co/d3WA3CRFRC
Dr. John Cush RheumNow ( View Tweet)
Review of Emerging Treatments for Vitiligo an immune mediated dz that affects QOL & has psychosocial impact. JAKi only ruxolitinib is FDA-approved, but Tofa & Bari show promise. Emerging therapies include simvastatin, afamelanotide, and metformin https://t.co/Rp2yYx6SyZ https://t.co/pBo1IDe8pQ
Dr. John Cush RheumNow ( View Tweet)
IL-40 is elevated in systemic sclerosis (SSc). Study of serum (90 SSc vs controls/HCs), Skin Bx (5 SSc v 5 HCs). IL-40 signific. upregulated in the skin & correl. w/ ESSG (r = 0.37), GI dz; also w/ serum IL-8, TGF-β1. IL-40 functionally linked to activated B cells, PMNs, T https://t.co/2sIgMYK7xo
Dr. John Cush RheumNow ( View Tweet)
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/6yyxVIxpC0
Dr. John Cush RheumNow ( View Tweet)
Lupus Clinical Slides: Set 1
https://t.co/zFQqHfl8Ch https://t.co/kvVNAS17ec
Dr. John Cush RheumNow ( View Tweet)
Lupus QD Clinic - Rhupus
dsDNA+ SLE Plus CCP+ RA = Rhupus
https://t.co/lyV7fgd1vp https://t.co/Ptw0dmyqCj
Dr. John Cush RheumNow ( View Tweet)
The ANA pattern I hate
#DFS
Why
Dense fine speckled should R/O #SLE
But mimicking patterns that MAY Have #lupus
AC-2 pattern mimickers ex AC-4
Machine learning models to help
▶️improved accuracy
Fast saving hrs
#Artificial #intelligence
May Choi #LUPUS2025 @RheumNow https://t.co/9tk80ZOAWg
Janet Pope Janetbirdope ( View Tweet)
Any ‘toll’ in #toll #like #receptors 7,8 in #SLE
Cutaneous #lupus
In #systemic or #cutaneous wk16
Rx
PBO
V
#enpatoran
No obvious dose response - all 3 dose >PBO
Safe so far improves IFN
No toll to pay! 👍
But need Ph3 data
#LUPUS2025 @EricFMorand @RheumNow https://t.co/2DDztlVsUm
Links:
Janet Pope Janetbirdope ( View Tweet)
Vitiligo affects up to 2% of people globally; more in blacks & hispanics than whites & more common in women > men. The prevalence has increased over time. Oral corticosteroids are most frequently prescribed, followed by other immunosuppressive drugs https://t.co/wNh6z3lKg1 https://t.co/hQo9sNn4kg
Dr. John Cush RheumNow ( View Tweet)
J&J announced results of Phase 3 ICONIC-TOTAL study of qd icotrokinra, an oral IL-23 receptor inhibitor, in 311 ps w/ difficult scalp and genital psoriasis (PSO) -success in 57%; skin clearance in 66% & genital psoriasis resp in 77% treated https://t.co/WftyEcDh8u https://t.co/Ydy37Eo0jX
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d
Links:
Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher https://t.co/l0QjM9obk2
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/aXgveR2NwF https://t.co/9JK6CNqedO
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher Richardson https://t.co/UNazbo9TuZ
Dr. John Cush RheumNow ( View Tweet)
